Christian Leisner
56 posts
Christian Leisner
@ChrisLeisner
Drug developer & biotech entrepreneur
Zurich, Switzerland Beigetreten Haziran 2008
35 Folgt22 Follower
Christian Leisner retweetet
Top 5 advances in medicine this week (🧵)
1. A drug that beats chemotherapy in a subset of lung cancers
Small cell lung cancer is usually treated with chemotherapy, but resistance is common, and side-effects can be severe
Tarlatamab is a bispecific antibody: it recruits T cells directly to cancer cells - via a protein expressed by ~90% of small cell lung cancers (called DLL3)
Tarlatamab has accelerated approval to treat small cell lung cancer as second line after platinum chemotherapy - this phase 3 trial provides the data to (potentially) upgrade this to full approval
Tarlatamab improved overall survival vs. physician’s choice of chemotherapy, with fewer grade 3 adverse events (though with a new side-effect - cytokine release syndrome)
Ongoing phase 3 trials are testing Tarlatamab as part of first-line combinations
nejm.org/doi/full/10.10…
English
Treasury Secretary Scott Bessent trying to walk it all back after alienating our allies:
"I wish to be clear: America first does not mean America alone. To the contrary, it is a call for deeper collaboration and mutual respect among trade partners."
The art of the cave.
🤦♀️
English
Christian Leisner retweetet
Say hello to Sophie Barsin, our Portfolio Management expert! Her unique perspective complements our scientists' expertise, creating a balanced approach that drives project success and helps guides promising research toward meaningful outcomes.
Learn more cdr-life.com
English
Christian Leisner retweetet
Pipeline Expansion: CDR111, novel trispecific molecule for immune reset in autoimmune diseases! Plus, oncology updates at #AACR25! Join us on April 28 for TCE data:
· CDR404 – Potential best-in-class MAGE-A4 TCE
· Novel TCE for HLA-A*01/KK-LC-1 tumors
bit.ly/43UTVfM
English
Christian Leisner retweetet
Excited to hold our first Autoimmune Scientific Advisory Board meeting today! With CDR404's clinical progress & our new CDR111 (CD3xCD19xBCMA trispecific) for immune reset, our proprietary antibody-based M-gager® platform expands our unique T cell engager approach to autoimmunity
English
Now treating cancer patients
CDR-Life@CDRLifeBiotech
#NEWS: CDR-Life hits major milestones in cancer immunotherapy! ✅ First patient dosed with CDR404 (MAGE-A4 target) ✅ CDR813 (PRAME target) advances as promising clinical candidate Our M-gager® tech is pushing boundaries in solid tumor treatment. lnkd.in/e2VQrW4X
English
Christian Leisner retweetet
#NEWS: Following Phase I results, we're planning to advance a potential new treatment of Geographic Atrophy. We developed the antibody BI 771716 using technology licensed from @CDRLifeBiotech
Learn more 👉 bit.ly/3zadtQv
#RetinalDiseases #ClinicalTrials #VisionHealth
English
Ph 1 being key with this approach, proud to see the positive clinical data from @Boehringer with a @CDRLifeBiotech originated molecule
CDR-Life@CDRLifeBiotech
#NEWS: With licensed technology developed by CDR-Life, @Boehringer announces positive Phase 1 results for BI 771716, an antibody fragment-based treatment for geographic atrophy, a major cause of vision loss. Learn more 👉#latest" target="_blank" rel="nofollow noopener">cdr-life.com/news/#latest
English
In September and October, I’ll be spending a lot of time in Europe for BiotechTV. If you are an EU company that has news, or know of cool science, reach out. I’m starting to schedule.
English
Christian Leisner retweetet
Great news! CDR-Life expands its innovative cancer therapy portfolio with the addition of two highly tumor-targeted T cell engagers (TCE): CDR813 and CDR505: Read more:bit.ly/4bldGNA
English
Christian Leisner retweetet
CDR-Life has announced that Chief Medical Officer Swethajit Biswas will co-lead a seminar on translational insights into cell engager drugs at the 6th Annual Cell Engager Summit on May 21 in Boston. cdr-life.com/news/
English
Christian Leisner retweetet
Congrats to @Amgen on FDA approval of the second ever T cell Engager therapy in solid tumors. It is so exciting to see great progress being made in the T cell engager space. x.com/Amgen/status/1…
Amgen 🧪🔬🧬@Amgen
The @US_FDA has approved Amgen’s treatment for adults with extensive-stage small cell lung cancer (ES-SCLC). This option is the first BiTE ® therapy for ES-SCLC. 🔗 Press release: amgen.ly/4blqtR1 $AMGN
English
@LeoBorrasLife will be talking about CDR-Life’s leading T cell engager technology.
CDR-Life@CDRLifeBiotech
CDR-Life has announced a presentation on its proprietary antibody-MHC technology for the development of highly specific T-cell engagers at the TCR-Based Therapies for Solid Tumors Summit: cdr-life.com/news/
English
Christian Leisner retweetet
CDR-Life has announced a presentation on its proprietary antibody-MHC technology for the development of highly specific T-cell engagers at the TCR-Based Therapies for Solid Tumors Summit: cdr-life.com/news/
English
If you are in San Diego at #AACR24, check out our exciting new T cell engager target
CDR-Life@CDRLifeBiotech
CDR-Life has announced the presentation of preclinical data demonstrating the promising anti-tumor properties of its peptide MHC T-cell engager antibodies at the #AACR24 Annual Meeting: cdr-life.com/news/
English
Thank you @cathshaffer for a great conversation about CDR-Life’s first M-gager IND
CDR-Life@CDRLifeBiotech
Check out this great article by @cathshaffer at Precision Medicine Online on how CDR-Life is developing a pipeline of antibody-based T-cell engagers directed to promising cancer targets: bit.ly/4be7isU
English